Lindbrook Capital’s Tourmaline Bio TRML Stock Holding History

Lindbrook Capital’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-56	Closed	-$1.14K	–	2934
2024 Q4	$1.14K	Hold	56	–	–	﹤0.01%	2456
2024 Q3	$1.44K	Buy	+56	New	+$935	﹤0.01%	2427

Other funds holding TRML

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Lindbrook Capital's TRML Position: Q1 2025 in Review

Lindbrook Capital sold out of Tourmaline Bio (TRML) in Q1 2025, closing a stake of 56 shares — an estimated $1.14K sold.

Lindbrook Capital first reported a position in TRML in Q3 2024 and held it in 2 quarters. The position peaked at $1.44K in Q3 2024. 107 funds tracked by Wall St. Rank hold TRML as of Q1 2025.

Lindbrook Capital reported no remaining Tourmaline Bio position as of Q1 2025 after selling out during the quarter.
Lindbrook Capital sold 56 Tourmaline Bio shares in Q1 2025, an estimated $1.14K.
Lindbrook Capital first reported a position in Tourmaline Bio in Q3 2024 and held it in 2 quarters.
Lindbrook Capital's Tourmaline Bio position peaked at $1.44K in Q3 2024.
107 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.